Rapid Clinical Improvement With Tyrosine Kinase 2 Inhibitor Deucravacitinib in Overlapping Psoriasis and Atopic Dermatitis
Year: 2025
Type: article
Abstract: The authors declare no conflicts of interest. The data supporting this study's findings are available from the corresponding author upon reasonable request.
DOI: 10.1111/ijd.17742
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: G1827997539, G4650702606
OpenAlex ID: W4409568038
